Unituxin

Search documents
United Therapeutics (UTHR) Reports Q1 Earnings: What Key Metrics Have to Say
ZACKSยท 2025-04-30 14:35
United Therapeutics (UTHR) reported $794.4 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 17.2%. EPS of $6.63 for the same period compares to $6.17 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $726.19 million, representing a surprise of +9.39%. The company delivered an EPS surprise of +5.41%, with the consensus EPS estimate being $6.29.While investors scrutinize revenue and earnings changes year-over-year and how they compare wit ...
United Therapeutics(UTHR) - 2025 Q1 - Earnings Call Transcript
2025-04-30 13:00
United Therapeutics (UTHR) Q1 2025 Earnings Call April 30, 2025 09:00 AM ET Company Participants Dewey Steadman - Head, IRMartine Rothblatt - Founder, Chairman & CEOMichael Benkowitz - President & COOLeigh Peterson - Executive Vice President of Product Development & XenotransplantationJames Edgemond - CFO & TreasurerAshwani Verma - Executive Director - SMID Biotech & Biopharma Conference Call Participants Joseph Thome - Managing Director, Senior Biotechnology AnalystJessica Fye - Managing Director & Equity ...
United Therapeutics(UTHR) - 2025 Q1 - Earnings Call Transcript
2025-04-30 13:00
United Therapeutics (UTHR) Q1 2025 Earnings Call April 30, 2025 09:00 AM ET Speaker0 Good morning and welcome to the United Therapeutics Corporation First Quarter twenty twenty five Corporate Update. My name is Torben and I will be your conference operator today. All participants on the call portion of this webcast will be in listen only mode until the question and answer portion of this earnings call. Please note, this call is being recorded. I would now like to turn the webcast over to Dewey Steadman, Hea ...
United Therapeutics(UTHR) - 2025 Q1 - Earnings Call Presentation
2025-04-30 10:36
Safe Harbor Statement All statements in this presentation are made as of April 30, 2025. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events, or otherwise. Statements included in this presentation that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements related to our revenue growth expec ...